Donanemab therapy in Alzheimer’s disease with mild cognitive impairment: Convergent amyloid, tau, and plasma biomarker normalization with cognitive improvement

Donanemab therapy in Alzheimer's disease with mild cognitive impairment: Convergent amyloid, tau, and plasma biomarker normalization with cognitive improvement Recently, I read with great interest the Appropriate Use Recommendations (AUR) for donanemab presented by Rabinovici et al. in the